GlassScriptPhysician profile
Jamie Harms
NPI 1780685073
$1,974.52
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $605 · 2021: $423 · 2022: $12.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.25 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $180.35 | 2019-2020 | |
| Amgen INC. | $163.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $88.83 | 2019-2021 | |
| Pfizer INC. | $75.01 | 2019 | |
| Lilly USA, LLC | $69.74 | 2020-2021 | |
| Glaxosmithkline, LLC. | $65.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.53 | 2019-2021 | |
| Abbvie INC. | $53.00 | 2021 | |
| Amarin Pharma, INC. | $47.19 | 2019-2021 | |
| Abbott Laboratories | $46.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.12 | 2019 | |
| Allergan, INC. | $40.05 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $34.42 | 2019 | |
| Hikma Pharmaceuticals USA | $28.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.84 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $27.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.70 | 2020 | |
| Lundbeck LLC | $18.47 | 2021 | |
| Eisai INC. | $17.64 | 2020 | |
| Alkermes, INC. | $16.20 | 2020 | |
| Philips North America LLC | $15.40 | 2020 | |
| Ibsa Pharma INC. | $12.75 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.65 | 2021 | |
| Medtronic, INC. | $12.22 | 2022 | |
| Dexcom, INC. | $11.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Harms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.